Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Autosomal dominant intermediate Charcot-Marie-Tooth disease type E is characterized by the association of Charcot-Marie-Tooth disease (hereditary peripheral neuropathy) with nephropathy. So far, around 15 cases have been described. All patients had proteinuria (with or without microhematuria) at onset and some patients presented with nephrotic syndrome. In the majority of cases, pathological studies revealed glomerulosclerosis. The mode of transmission is unknown.
Features include always present findings: Onion bulb formation, Areflexia, Distal muscle weakness, and Protein in the urine (proteinuria) and others; and very common findings: Stage 5 chronic kidney disease. 19 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Arms and legs | 4 | Claw hand deformity, Foot dorsiflexor weakness, Distal upper limb amyotrophy |
Brain and nerves | 3 | Hyporeflexia, Steppage gait, Peripheral neuropathy |
Kidneys and urinary system | 3 | Stage 5 chronic kidney disease, Focal segmental glomerulosclerosis, Protein in the urine (proteinuria) |
Muscles | 2 | Distal muscle weakness, Foot dorsiflexor weakness |
Lab test results | 1 | Elevated creatine kinase (muscle enzyme) (elevated circulating creatine kinase concentration) |
Ears | 1 | Inner ear hearing loss (sensorineural hearing impairment) |
INF2 encodes inverted formin 2 (1,249 aa). Severs actin filaments and accelerates their polymerization and depolymerization Highest expression in Nerve Tibial (204.3 TPM) and Artery Tibial (83.1 TPM).
Charcot-Marie-Tooth disease dominant intermediate E is caused by mutations in the INF2 gene on chromosome 14.
INF2 is classified as a druggable target with score 0.0.
Genetic testing for INF2 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 8 always present features, 1 very common feature, 2 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for Charcot-Marie-Tooth disease dominant intermediate E.
3 publications have been identified in PubMed for Charcot-Marie-Tooth disease dominant intermediate E. Research spans Epidemiology / Natural History (67%) and Review / Meta-Analysis (33%).
Yano C (2026). [PMID: 40985697](https://pubmed.ncbi.nlm.nih.gov/40985697/). *Ann Clin Transl Neurol*. [Epidemiology / Natural History]
Cakar A (2025). [PMID: 39776111](https://pubmed.ncbi.nlm.nih.gov/39776111/). *Eur J Neurol*. [Epidemiology / Natural History]
Labat-de-Hoz L (2024). [PMID: 39586895](https://pubmed.ncbi.nlm.nih.gov/39586895/). *Cell Mol Life Sci*. [Review / Meta-Analysis]
Data assembled from 7 of 12 sources · Last updated Sep 19, 2026, 7:54 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Charcot-Marie-Tooth disease dominant intermediate E